Lexilium

Bromazepam, the active ingredient in Lexilium, is a benzodiazepine presented as an oral dosage form for oral use. It is prescribed for anxiety disorders and provides short‑term relief of anxiety symptoms in adult patients. The medication acts centrally to reduce excessive neuronal activity associated with heightened anxiety.

GNH USA supplies Lexilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, ensuring consistent quality, regulatory compliance and reliable delivery across EU and other global markets.

Bromazepam acts on the central nervous system to alleviate anxiety‑related conditions.

Generalized anxiety disorder: reduces excessive worry and tension, providing short‑term symptom control. Panic disorder: diminishes the intensity and frequency of panic attacks during acute phases. Situational anxiety (e.g., before surgery): offers rapid calming effect to facilitate procedures. Adjustment disorder with anxiety: helps stabilize mood and reduce anxious symptoms during stressful life changes. Preoperative anxiety: provides calming effect to improve patient cooperation before surgery. Acute stress reaction: alleviates transient anxiety and tension during emergency situations.

Bromazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: a feeling of sleepiness that may impair concentration and affect daily activities, especially when driving or operating machinery. - Fatigue: persistent lack of energy or increased tiredness that can reduce motivation and physical performance. - Dizziness: sensation of light‑headedness, vertigo or imbalance that may increase risk of falls. - Impaired coordination: reduced motor control leading to clumsiness, difficulty with fine motor tasks and occasional stumbling.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can become life‑threatening, particularly when combined with other central nervous system depressants such as alcohol, opioids or other benzodiazepines. - Severe hypotension: a marked drop in blood pressure that may cause faintness, dizziness, or in extreme cases, shock requiring immediate medical attention. - Paradoxical reactions: unexpected agitation, aggression, hostility or anxiety instead of the intended calming effect, which may necessitate discontinuation.

When prescribing Bromazepam, clinicians should consider several precautionary measures to minimise risks.

Avoid abrupt discontinuation: taper the dose gradually to prevent withdrawal symptoms. Use caution in elderly patients: increased sensitivity may lead to excessive sedation or falls. Monitor for depression or suicidal thoughts: anxiety relief may unmask underlying mood disorders. Avoid concomitant alcohol: combined depressant effect can intensify sedation and respiratory depression. Assess liver function: bromazepam is metabolised in the liver, and dose adjustment may be required in severe hepatic impairment. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Bromazepam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression that can lead to profound sedation, impaired judgment and increased risk of accidents. - Opioids: combined depressant effect may cause severe respiratory depression, profound sedation and heightened overdose potential. - Other benzodiazepines: concurrent use results in cumulative sedation, marked psychomotor impairment and an increased risk of dependence and withdrawal complications.

Moderate Interactions (Monitor Closely): - Antidepressants (especially SSRIs): may enhance the sedative properties of bromazepam, requiring careful observation of drowsiness and possible dose adjustment. - Antihistamines: can increase drowsiness and impair psychomotor performance, so activities such as driving should be approached with caution. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise bromazepam plasma concentrations, necessitating therapeutic monitoring and possible dose reduction.